Drug Profile
DA 3201
Alternative Names: DA-3201; Recombinant basic fibroblast growth factor (DA-3201)Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Antivirals; Fibroblast growth factors; Growth factors; Interferons
- Mechanism of Action Fibroblast growth factor receptor modulators; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease; Hepatitis C
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in South Korea (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in South Korea
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea